Which GLP-1 Is Right for You? Quiz
Answer 6 quick questions to get a personalized suggestion for semaglutide vs tirzepatide.
Disclaimer: This quiz is for informational purposes only. Medication selection should always be made with a licensed healthcare provider based on your individual health profile.
Question 1 of 6
What is your primary goal?
Frequently Asked Questions
Is this quiz a substitute for medical advice?
No. This quiz provides general guidance based on common factors providers consider. Your healthcare provider will evaluate your complete medical history, labs, and individual circumstances to recommend the best medication for you.
Can I switch medications if one does not work?
Yes. Many patients switch between semaglutide and tirzepatide based on response, tolerability, and goals. Your provider can guide a safe switching protocol, typically transitioning at comparable dose levels.
What if both medications seem equally good for me?
That is common. Both are excellent medications. In that case, other factors like cost, insurance coverage, and provider familiarity may guide the decision. Starting with one and adjusting based on response is a reasonable approach.
Are there other GLP-1 options beyond semaglutide and tirzepatide?
Yes. Liraglutide (Saxenda) is another FDA-approved weight loss medication. Retatrutide and other next-generation options are in development. Your provider can discuss all available options based on your needs.
Get Personalized Guidance
A Trimi clinician will evaluate your full health profile to recommend the best GLP-1 medication for you.
Start Your ConsultationMore on Calculators & Tools
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).